CN115702146A - 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用 - Google Patents

5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用 Download PDF

Info

Publication number
CN115702146A
CN115702146A CN202180042136.7A CN202180042136A CN115702146A CN 115702146 A CN115702146 A CN 115702146A CN 202180042136 A CN202180042136 A CN 202180042136A CN 115702146 A CN115702146 A CN 115702146A
Authority
CN
China
Prior art keywords
cycloalkyl
independently selected
alkyl
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042136.7A
Other languages
English (en)
Inventor
陈科
蒋钰
张长青
季明华
罗欢
金雪梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Enhua Biomedical Technology Co ltd
Nhwa Pharmaceutical Corp
Original Assignee
Suzhou Enhua Biomedical Technology Co ltd
Nhwa Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Enhua Biomedical Technology Co ltd, Nhwa Pharmaceutical Corp filed Critical Suzhou Enhua Biomedical Technology Co ltd
Publication of CN115702146A publication Critical patent/CN115702146A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种5‑((1,2,3,4‑四氢异喹啉‑7‑基)氨基)吡啶‑2(1H)‑酮衍生物及其制备方法及应用，其具有如式(I’)所示的化合物结构，该类化合物对sigma‑1受体具有高药理活性以及高选择性，可用于中枢神经疾病的治疗和预防，特别是可用于制备抗抑郁、抗焦虑的药物。
Figure DDA0003993124080000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180042136.7A 2020-06-30 2021-06-30 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用 Pending CN115702146A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010616096 2020-06-30
CN202010616096X 2020-06-30
PCT/CN2021/103543 WO2022002131A1 (zh) 2020-06-30 2021-06-30 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用

Publications (1)

Publication Number Publication Date
CN115702146A true CN115702146A (zh) 2023-02-14

Family

ID=79317436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042136.7A Pending CN115702146A (zh) 2020-06-30 2021-06-30 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用

Country Status (2)

Country Link
CN (1) CN115702146A (zh)
WO (1) WO2022002131A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017190109A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
CN109280030A (zh) * 2017-07-19 2019-01-29 江苏恩华药业股份有限公司 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用
WO2019133770A2 (en) * 2017-12-29 2019-07-04 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
CN112812061A (zh) * 2019-12-10 2021-05-18 江苏恩华药业股份有限公司 N-芳基-1,2,3,4-四氢异喹啉-7-胺化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017190109A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
CN109280030A (zh) * 2017-07-19 2019-01-29 江苏恩华药业股份有限公司 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用
WO2019133770A2 (en) * 2017-12-29 2019-07-04 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
CN112812061A (zh) * 2019-12-10 2021-05-18 江苏恩华药业股份有限公司 N-芳基-1,2,3,4-四氢异喹啉-7-胺化合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
杨兆青，等: "靶向Ｓｉｇｍａ⁃１ ／ ５⁃ＨＴ１Ａ 受体的四氢异喹啉类化合物的 设计合成及生物活性评价", 《中国药物化学杂志》, vol. 30, no. 1, 31 January 2020 (2020-01-31), pages 1 - 9 *

Also Published As

Publication number Publication date
WO2022002131A1 (zh) 2022-01-06

Similar Documents

Publication Publication Date Title
EP3478674B1 (en) 4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN108884101B (zh) 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
US8841318B2 (en) Substituted heterocycles as janus kinase inhibitors
EP1896470B1 (en) Pyrrolopyridine derivatives as protein kinase inhibitors
CA3115830C (en) Compounds for inhibition of .alpha.4.beta.7 integrin
AU2017287553B2 (en) Imidazopyrazinamine phenyl derivative and use thereof
CA3116769C (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
CA2908098A1 (en) Mk2 inhibitors and uses thereof
CA3114240A1 (en) Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN107151249B (zh) 作为flt3抑制剂的蝶啶酮衍生物及应用
TW201311687A (zh) 經取代之咪唑並吡啶基－胺基吡啶化合物類
WO2010085597A1 (en) Macrocyclic compounds and their use as kinase inhibitors
CN106928219A (zh) 含氮稠杂环化合物、制备方法、中间体、组合物和应用
EP3661935B1 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
TW202200575A (zh) 一種免疫抑制劑、其製備方法和應用
WO2017211245A1 (zh) 一种取代的吡咯并嘧啶化合物及其应用
KR20140082710A (ko) 이미다조피리딘 화합물, 조성물 및 사용 방법
CN111978311B (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2020238179A1 (zh) 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
EP3865488A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
GB2083474A (en) N-(4-3-substituted pyridyl piperazino) alkyl azaspirodecanediones
CN108047207A (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
TW202132304A (zh) 腺苷受體拮抗劑化合物
TWI828289B (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
CN110467637B (zh) 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 215021 Building 6, Tengfei Innovation Park, No. 388, Xinping Street, Suzhou Industrial Park, Jiangsu Province

Applicant after: Suzhou Enhua Biomedical Technology Co.,Ltd.

Applicant after: NHWA PHARMA. Corp.

Address before: 215000 unit 303b, building A4, phase I project of biomedical industrial park, No. 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu Province

Applicant before: Suzhou Enhua Biomedical Technology Co.,Ltd.

Applicant before: NHWA PHARMA. Corp.

CB02 Change of applicant information